Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SOX9 drives WNT pathway activation in prostate cancer
Fen Ma, … , Steven P. Balk, Xin Yuan
Fen Ma, … , Steven P. Balk, Xin Yuan
Published April 4, 2016
Citation Information: J Clin Invest. 2016;126(5):1745-1758. https://doi.org/10.1172/JCI78815.
View: Text | PDF
Research Article Oncology

SOX9 drives WNT pathway activation in prostate cancer

  • Text
  • PDF
Abstract

The transcription factor SOX9 is critical for prostate development, and dysregulation of SOX9 is implicated in prostate cancer (PCa). However, the SOX9-dependent genes and pathways involved in both normal and neoplastic prostate epithelium are largely unknown. Here, we performed SOX9 ChIP sequencing analysis and transcriptome profiling of PCa cells and determined that SOX9 positively regulates multiple WNT pathway genes, including those encoding WNT receptors (frizzled [FZD] and lipoprotein receptor-related protein [LRP] family members) and the downstream β-catenin effector TCF4. Analyses of PCa xenografts and clinical samples both revealed an association between the expression of SOX9 and WNT pathway components in PCa. Finally, treatment of SOX9-expressing PCa cells with a WNT synthesis inhibitor (LGK974) reduced WNT pathway signaling in vitro and tumor growth in murine xenograft models. Together, our data indicate that SOX9 expression drives PCa by reactivating the WNT/β−catenin signaling that mediates ductal morphogenesis in fetal prostate and define a subgroup of patients who would benefit from WNT-targeted therapy.

Authors

Fen Ma, Huihui Ye, Housheng Hansen He, Sean J. Gerrin, Sen Chen, Benjamin A. Tanenbaum, Changmeng Cai, Adam G. Sowalsky, Lingfeng He, Hongyun Wang, Steven P. Balk, Xin Yuan

×

Figure 5

SOX9-associated WNT pathway enrichment and expression of WNT signaling components in clinical PCa data sets.

Options: View larger image (or click on image) Download as PowerPoint
SOX9-associated WNT pathway enrichment and expression of WNT signaling c...
(A) GSEA of the WNT signaling pathway comparing SOX9 high and SOX9 low samples in the TCGA PCa data set. NES = 1.11. (B) The box plot demonstrates the differential expression of various WNT pathway components between the SOX9 high (SH, n = 60) and SOX9 low groups (SL, n = 85) from a cohort of 195 patients in the TCGA data set. Unpaired t test was used. (C) GSEA of the WNT signaling pathway in an MSKCC PCa data set comparing SOX9 high and SOX9 low samples. NES = 1.05. (D) The box plot demonstrates the differential expression of WNT components in the SOX9 high (n = 36) and SOX9 low groups (n = 28) from a cohort of 131 patients in the MSKCC data set. Unpaired t test was used. (B and D) In box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate 10th and 90th percentiles. (E and F) Enrichment profiles of the WNT activation signature adapted from ref. 43 comparing patients with high versus low levels of SOX9 expression in the TCGA (E) or MSKCC (F) data sets. The NES are 1.28 and 1.60, respectively.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts